Clinical trials: Mental Depression
Non-psychotic Unipolar Major Depression
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial
A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about…
- Trial name
- PANTHER (NCT01887639)
- Where
- 8 sites in Argentina
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8…
- Trial name
- NCT04221230
- Testing
- NMRA-335140
- Where
- 38 sites in United States
- Volunteers
- 204 people
- Sponsor
- Neumora Therapeutics, Inc.
Depression
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social…
- Trial name
- NCT04524598
- Testing
- Limbix Spark, Psychoeducation
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158533
- Testing
- High Dose ALKS 5461, Low Dose ALKS 5461
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 385 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250614
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Sanofi
Depressive Disorder
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail…
- Trial name
- NCT01046214
- Testing
- Bupropion HCl
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Teva Pharmaceuticals USA
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Major Depressive Disorder
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
This study was a non-randomized, open-label clinical study to assess Serotonin transporter occupancy in the brain of healthy adults using 11C-DASB positron emission tomography (PET)
- Trial name
- NCT06476509
- Testing
- LV232 40mg, Escitalopram 20 mg, LV232 60mg
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Major Depressive Disorder
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in…
- Trial name
- NCT07196501
- Testing
- Osavampator
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 550 people
- Sponsor
- Neurocrine Biosciences
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Depressive Disorder, Major
A Safety, Efficacy and Tolerability Study of SEP-225289
To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder
- Trial name
- NCT00584974
- Testing
- SEP-225289, Venlafaxine
- Where
- 51 sites in United States
- Volunteers
- 523 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Episode
Medibio DDA Confirmatory Performance Study
This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.
- Trial name
- NCT03529513
- Testing
- Medibio Depression Diagnostic Aid, Mini International Neuropsychiatric Interview, Hamilton Rating Scale for Depression - 17 Item
- Where
- 8 sites in United States, Australia
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Medibio Limited
Premenstrual Syndrome, Premenstrual Dysphoric Disorder
CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life
This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device…
- Conditions
- Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Dysmenorrhea, Endometriosis
- Trial name
- CREST (NCT07679074)
- Testing
- Lutea Transcranial Direct Current Stimulation (tDCS) Device, Samphire Guided Care Program
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samphire Group, Inc.
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Depression
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD)…
- Trial name
- NCT02918318
- Testing
- Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg)
- Where
- 43 sites in Japan
- Volunteers
- 202 people
- Sponsor
- Janssen Pharmaceutical K.K.
Depression, Bipolar Disorder
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
- Trial name
- NCT03403790
- Testing
- Quetiapine
- Where
- 47 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).
- Trial name
- NCT03672175
- Testing
- SAGE-217
- Where
- 53 sites in United States
- Volunteers
- 581 people
- Sponsor
- Biogen
Depressive Disorder, Major
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at…
- Trial name
- NCT01138007
- Testing
- 323U66 SR 150 mg tablet
- Where
- 59 sites in Japan, South Korea
- Volunteers
- 572 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.